Aaron Bloomer
Chief Financial Officer at Exact Sciences
Looking at free cash flow cadence, we expect a meaningful build in our AR balance as we launch Cologuard plus temporarily impacting our cash flow in Q2. We expect to collect on these in the back half of the year, driving our full year cash flow to a new record. We ended the quarter with cash and securities of $786,000,000 which reflects the $249,000,000 convertible note paydown. Turning to guidance. We are increasing total revenue guidance to between 3,070,000,000.00 and $3,120,000,000 for the year, an increase of $40,000,000 at midpoint, with second quarter revenue between $765,000,000 and $780,000,000 This assumes screening revenue between $595,000,000 and $6.00 $5,000,000 for the second quarter and between $2,390,000,000 and $2,425,000,000 for the year and Precision Oncology revenue between 170,000,000 and $175,000,000 for the second quarter and between $680,000,000 and $695,000,000 for the full year.